English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 61345/61345 (100%)
造訪人次 : 16286414      線上人數 : 233
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧:
  • 您可在西文檢索詞彙前後加上"雙引號",以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋,建議至進階搜尋限定作者欄位,可獲得較完整資料
  • 進階搜尋


    請使用永久網址來引用或連結此文件: http://ir.lib.ncu.edu.tw/handle/987654321/71436


    題名: PDE4與PDE3抑制劑對膠原蛋白誘發DBA/1小鼠關節炎及釋放發炎激素IFN-γ與IL-17A的協同調控作用;PDE4 and PDE3 Inhibitors Synergistically Inhibit Collagen-Induced Arthritis and IFN-γ and IL-17A Release in DBA/1 Mice
    作者: 陳仕祐;Chen,Shih-Yu
    貢獻者: 生命科學系
    關鍵詞: 類風濕性關節炎;膠原蛋白誘發關節炎;CD4+ T 細胞;IFN-γ;IL-17A;rheumatoid arthritis;collagen-induced arthritis;CD4+ T cell;IFN-γ;IL-17A
    日期: 2016-08-24
    上傳時間: 2016-10-13 13:04:17 (UTC+8)
    出版者: 國立中央大學
    摘要: 類風濕性關節炎(Rheumatoid arthritis, RA)是一種關節病變的慢性發炎自體免疫疾病,其發病機制相當複雜,確切病因至今仍甚不明瞭。許多研究顯示,提升免疫發炎細胞內cAMP濃度可降低發炎介質產生並改善發炎作用。而環狀核苷酸磷酸二酯酶4 (phosphodiesterase 4, PDE4)為免疫細胞中主要水解cAMP的酵素,因此可調控該細胞內cAMP濃度,進而影響免疫功能。臨床上,PDE4抑制劑Roflumilast與Apremilast已分別被用來治療慢性阻塞性肺病(COPD)、牛皮癬與牛皮癬關節炎。有文獻指出,PDE4抑制劑在RA小鼠模型實驗中可有效降低關節炎的發生率及發炎程度,並減少血管翳的形成和降低軟骨受損,但其作用機制仍有待釐清。已知CD4+ T細胞亞群Th1及Th17與RA的致病過程息息相關,因此本研究利用膠原蛋白誘發小鼠關節炎(collagen-induced arthritis, CIA)模型進一步探討增加cAMP或抑制PDE4是否可調控Th1及Th17細胞釋放IFN-γ與IL-17A並影響關節發炎程度。結果顯示,以第二型膠原蛋白(type II collagen, CII)激臖之DBA/1小鼠,其局部淋巴結細胞(來自i.d./i.d.模型)釋放IFN-γ及IL-17A量與CII處理呈專一性劑量反應關係。再者,免疫小鼠之脾臟細胞(來自i.d./i.p.模型)也有相同的結果。進一步研究顯示,以CII刺激i.d./i.d.模型之淋巴結細胞與i.d./i.p.模型之脾臟細胞,其Th1細胞激素IFN-γ的釋放會被cAMP增升劑dibutyryl-cAMP、adenylyl cyclase活化劑forskolin與PDE4抑制劑rolipram顯著抑制,表示rolipram是藉由增加Th1細胞內cAMP以減低IFN-γ的生成。再者,i.d./i.p.模型之脾臟細胞,而非i.d./i.d.模型之淋巴結細胞,其釋放Th17細胞激素IL-17A也會有相似的抑制作用。此外,PDE3抑制劑cilostazol也會顯著降低IFN-γ與IL-17A的釋放,只是抑制程度較rolipram輕微。實驗進一步使用CII致敏(primed)小鼠之局部淋巴結和脾臟細胞並以anti-CD3與anti-CD28抗體刺激其IFN-γ與IL-17A釋放,結果顯示兩種細胞產生IFN-γ主要也是由PDE4所調控,至於IL-17A,PDE4抑制劑只能顯著降低脾臟細胞的作用而無法抑制淋巴結細胞的反應。值得注意的是,在不同模型中,同時以rolipram與cilostazol處理兩種細胞幾乎可完全抑制IFN-γ與IL-17A釋放,這表示兩種抑制劑具有協同抑制作用。為此,我們進一步使用rolipram與cilostazol進行活體實驗,結果顯示兩種抑制劑合併處理CIA小鼠可顯著抑制其關節發炎程度。再者,利用PDE4B基因剔除鼠進行CIA模型實驗得知,單獨剔除PDE4B基因無法減緩小鼠關節發炎作用,然而將cilostazol施予PDE4B基因剔除小鼠,其關節發炎程度較對照組PDE4B野生型小鼠則有顯著改善。綜合上述結果得知,抑制PDE4可有效減低CII誘導Th1與Th17免疫發炎反應,而PDE3抑制劑則具有協同抑制作用。因此我們推論研發PDE4與PDE3雙效抑制劑(dual inhibitors)將有助於減緩RA病情。;Rheumatoid arthritis (RA) is a chronic, inflammatory, autoimmune disease. It targets multiple joints with complex pathological processes. To date, the etiology of RA is not fully understood. Accumulating evidence indicates that cAMP-elevating agents can negatively modulate many inflammatory responses in virtually all immune inflammatory cells and thereby ameliorate inflammatory diseases. Type 4 phosphodieasterases (PDE4s) are the predominant cAMP-hydrolyzing enzymes in most immune cells, hence being important in controlling the intracellular cAMP concentration and immune functions. So far, the PDE4 inhibitors Roflumilast and Apremilast are used in clinic to treat chronic obstructive pulmonary disease (COPD) and psoriasis and psoriatic arthritis, respectively. Using the animal models of RA, several studies have shown that the incidence and severity of arthritis as well as articular pannus formation and cartilage damage are significantly reduced by PDE4 inhibitors in experimantal animals. However, the molecular mechanisms of these effects still remain unclear. It is known that the helper Th1 and Th17 cells are involved in the pathogenesis of RA by secreting the cytokines IFN-γ and IL-17A, respectively. Thus, in this study we used collagen-induced arthritis (CIA) model to determine whether inhibition of PDE4 can regulate the IFN-γ and IL-17A release as well as the arthritic severity in CIA mice. Using type II collagen (CII) to immunize DBA/1 mice by two protocols (i.e., i.d./i.d. and i.d./i.p. models), we first observed that CII-induced IFN-γ and IL-17A release in local lymph node cells (by i.d./i.d. model) and spleen cells (by i.d./i.p. model) was dose dependently increased. The secretion of Th1 cytokine IFN-γ in both tissue cells was significantly decreased by dibutyryl-cAMP (cAMP analog) and forskolin (adenylyl cyclase activator), as well as by the PDE4 inhibitor rolipram, indicating that the inhibitory effect of rolipram was mediated by an increase of cAMP in Th1 cells. In addition, the release of IL-17A in the spleen cells, but not the lymph node cells also was suppressed by these cAMP-elevationg agents. Moreover, like rolipram, the PDE3 inhibitor cilostazol also significantly attenuated the secretion of IFN-γ and IL-17A while having less extent. In a CII-primed model, anti-CD3/CD28 antibody-induced IFN-γ release in the mouse local lymph node and spleen cells was also significantly reduced by rolipram, but not by cilostazol. As for IL-17A, inhibition of PDE4 caused a significant decrease in IL-17A release in the spleen cells but not the lymph node cells. It was noted that in all CIA models tested IFN-γ and IL-17A release was almost completely inhibited when the two tissue cells were treated with rolipram in combination with cilostazol. Thus, the two inhibitors were used together to treat CIA mice and the results showed that the inhibition of both PDE4 and PDE3 significantly attenuated the arthritic severity. Moreover, using the CIA model in the PDE4B null mice revealed that ablation of PDE4B did not affect the development of arthritis, while administration of cilostazol to PDE4B null mice appeared to reduce the disease severity when compared with the control wild type mice. Taken together, these results indicate that inhibition of PDE4 can effectively reduce the CII-induced Th1 and Th17 responses, and inhibition of PDE3 exerts synergistic inhibitory effects in CIA mice. Our findings provide an experimental basis for developing PDE3/4 dual inhibitors for RA therapy.
    顯示於類別:[生命科學研究所 ] 博碩士論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    index.html0KbHTML198檢視/開啟


    在NCUIR中所有的資料項目都受到原著作權保護.

    社群 sharing

    ::: Copyright © National Central University. | 國立中央大學圖書館版權所有 | 收藏本站 | 設為首頁 | 最佳瀏覽畫面: 1024*768 | 建站日期:8-24-2009 :::
    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋  - 隱私權政策聲明